A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
• 18 to 75 years old, both male and female;
• ECOG score: 0-1;
• Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;
• Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;
• Measurable lesions available;
• Major organ function is basically normal;
• Estimated survival time is at least 6 months;
• Non-surgically sterile female subjects of childbearing age must have a negative serum HCG test before inclusion.